France-based Sanofi SA posted strong sales and business operating income for the 2025 first quarter due to continued demand for Dupixent and a strong performance by newer treatments and vaccines. Sales reached €9.9 billion, up by 10.8% in actual exchange rates and by 9.7% at constant rates. Business operating income for the quarter was €2.9 billion, a rise of 20.1% on the first quarter of 2024. The company left its full-year profit and sales forecasts unchanged, with the expectation that sales will continue to grow strongly.
